Pharmacometabonomic association of cyclophosphamide 4‐hydroxylation in hematopoietic cell transplant recipients
Abstract The widely used alkylating agent cyclophosphamide (CY) has substantive interpatient variability in the area under the curve (AUC) of it and its metabolites. Numerous factors may influence the drug‐metabolizing enzymes that metabolize CY to 4‐hydroxycyclophosphamide (4HCY), the principal pre...
Saved in:
Main Authors: | Jeannine S. McCune (Author), Ryotaro Nakamura (Author), Denis O'Meally (Author), Timothy W. Randolph (Author), Brenda M. Sandmaier (Author), Aleksandra Karolak (Author), David Hockenbery (Author), Sandi L. Navarro (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2022-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Lipidomics of cyclophosphamide 4‐hydroxylation in patients receiving post‐transplant cyclophosphamide
by: Sandi L. Navarro, et al.
Published: (2022) -
The presence of busulfan metabolites and pharmacometabolomics in plasma drawn immediately before allograft infusion in hematopoietic cell transplant recipients
by: Jeannine S. McCune, et al.
Published: (2023) -
Challenges with sirolimus experimental data to inform QSP model of post‐transplantation cyclophosphamide regimens
by: Ezhilpavai Mohanan, et al.
Published: (2024) -
Phenotyping Study of Cyclophosphamide 4-Hydroxylation in Malay Cancer Patients
by: Fityatal Hasanah YI, et al.
Published: (2021) -
From Metabonomics to Pharmacometabonomics: The Role of Metabolic Profiling in Personalised Medicine
by: Jeremy Everett
Published: (2016)